Sign In
Buy ADVM
$4.36
+0 (+0%)
At Close: Mar 06, 2026
Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
07:00am, Friday, 02'nd Aug 2024
REDWOOD CITY, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly p
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
10:41am, Thursday, 18'th Jul 2024
Here is how Adverum Biotechnologies (ADVM) and Medpace (MEDP) have performed compared to their sector so far this year.
Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript
03:35pm, Wednesday, 17'th Jul 2024
Adverum Biotechnologies, Inc. (NASDAQ:ADVM ) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Call July 17, 2024 8:00 AM ET Company Participants Mike Zanoni - Head of IR Laurent Fischer - Pre
- 6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks
Wall Street Analysts Think Adverum Biotechnologies (ADVM) Could Surge 290.54%: Read This Before Placing a Bet
10:56am, Tuesday, 16'th Jul 2024
The mean of analysts' price targets for Adverum Biotechnologies (ADVM) points to a 290.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme
Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
10:36am, Friday, 10'th May 2024
Adverum Biotechnologies (ADVM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earn
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
04:05pm, Thursday, 09'th May 2024
- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17 th , 2024 in Stockholm, Sweden
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
08:00am, Friday, 03'rd May 2024
REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly pr
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:05am, Thursday, 02'nd May 2024
Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
04:05pm, Thursday, 25'th Apr 2024
REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?
10:46am, Tuesday, 23'rd Apr 2024
Here is how Adverum Biotechnologies (ADVM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.
Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
10:36am, Friday, 19'th Apr 2024
Adverum Biotechnologies (ADVM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analys
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?
10:45am, Thursday, 04'th Apr 2024
Here is how Adverum Biotechnologies (ADVM) and Cigna (CI) have performed compared to their sector so far this year.
How Adverum (ADVM) Stock Stands Out in a Strong Industry
09:36am, Thursday, 04'th Apr 2024
Adverum (ADVM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround
10:36am, Wednesday, 03'rd Apr 2024
The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall St
